PV Bulletin
SwissmedicSwitzerland

Mandatory Registration for Medical Devices in Switzerland Starting 1 July 2026

Mandatory registration in swissdamed for medical devices and IVDs replaces existing notification procedures with effect from 1 July 2026.

PV Impact Brief

Urgency: HighConfidence: high
Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
ICSRCountry Compliance
Action needed

Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.

Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice
Policy status
effective
Publication date
2026-07-01
Policy change
Mandatory registration in swissdamed for medical devices and IVDs replaces existing notification procedures with effect from 1 July 2026. A transitional period applies until 31 December 2026 for most devices, but registration without a transitional period applies to devices that must be reported to Swissmedic due to serious incidents, FSCAs, or trends.

Key changes

Introduction of mandatory device registration in the swissdamed UDI Devices module; replacement of class I notifications; immediate registration required for vigilance-reportable incidents.

Affected workflows

ICSRCountry Compliance

PV impact

MAHs and manufacturers must use swissdamed for device registration and vigilance-related reporting (incidents, FSCAs, trends) from 1 July 2026 without a transitional period.

View regulator source

Source document details

Exact policy details

Mandatory registration start date
1 July 2026
Applies to: All medical devices, systems, and procedure packs placed on the market in Switzerland.
the introduction of mandatory registration in swissdamed · p. 1 · High · Source
Transitional period end date
31 December 2026
Applies to: Applies to devices, systems, and procedure packs for which sales units are placed on the market after 1 July 2026.
transitional period lasting until 31 December 2026 · p. 1 · High · Source
Registration fee for first device
CHF 200
Applies to: Fee for first UDI-DI registration per year.
A fee of CHF 200 will be charged for the first UDI-DI · p. 1 · High · Source
Registration fee for additional devices
CHF 20
Applies to: Fee for each additional UDI-DI with status 'On the market'.
a flat fee of CHF 20 will be charged for each additional UDI-DI · p. 1 · High · Source
Annual maximum fee
CHF 10,000
Applies to: Cost ceiling per manufacturer per calendar year.
subject to a cost ceiling of CHF 10,000 per calendar year · p. 1 · High · Source
First invoicing date
January 2027
Applies to: For devices registered by 31 December 2026.
The first invoices will be sent from January 2027 · p. 1 · High · Source

Workflow rule impacts

Country ComplianceManufacturer

Manufacturers must adapt their processes to ensure registration before market placement.

Mandatory registration of medical devices in swissdamed

Economic operators must register with Swissmedic before first placing a device on the market · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 1, 2026

Full briefing

What changed

The introduction of mandatory registration in swissdamed from 1 July 2026 replaces prior notification procedures for medical devices and IVDs.

Why it matters

This regulatory change enhances market surveillance and ensures that medical devices comply with safety standards before entering the market.

Practical implication

Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.

Related updates for your role

publicHealth Sciences Authority (HSA) · Singapore · Updated Jul 1, 2026

Proposed Regulation for Complementary Health Products in Singapore

Urgency: High

Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.

Country ComplianceSignal ManagementRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Consultation
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 1, 2026

Change to Patient Information and Information for Healthcare Professionals Templates

Urgency: High

MAHs must ensure new medicinal product information texts use updated templates by 1 July 2026 and revise existing texts at the earliest opportunity if they include instructions for use.

LabelingRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicHealth Sciences Authority (HSA) Singapore · Singapore · Updated Jun 30, 2026

Extension of e-labelling to P and GSL medicines

Urgency: High

Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.

LabelingRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead, QPPV
verifiedRegulatory action: Regulatory Update / Notice
Read impact briefarrow_forward
publicSaudi Food and Drug Authority (SFDA) · Saudi Arabia · Updated Jun 28, 2026

Regulations and Requirements for Conducting Clinical Trials on Drugs (Version 4.0)

Urgency: High

Ensure compliance with updated SUSAR reporting timelines (15 days), notify SFDA of Phase IV trials within 20 working days post-IRB approval, and prepare for the financial fee of 15,000 Saudi Riyals for clinical trial evaluations.

Country ComplianceICSRRegulatory Intelligence Lead
SOP Impact3 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead, QPPV
verifiedRegulatory action: Regulation
Read impact briefarrow_forward